
<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>World Pharma News / Published News</title>
<link>http://www.worldpharmanews.net</link>
<description>World Pharma News .net - Web 2.0 pharmaceutical news portal  votes</description>
<pubDate>Fri, 16 May 2008 00:03:33 CEST</pubDate>
<language>en</language>
<item>
<title><![CDATA[Pfiser's List of Grants and Charitable Contributions]]></title>
<link>http://www.worldpharmanews.net/Corporate/Pfisers_List_of_Grants_and_Charitable_Contributions/</link>
<comments>http://www.worldpharmanews.net/Corporate/Pfisers_List_of_Grants_and_Charitable_Contributions/</comments>
<pubDate>Fri, 16 May 2008 00:03:33 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/Pfisers_List_of_Grants_and_Charitable_Contributions/</guid>
<description><![CDATA[Pfizer announced that it has posted a list of U.S. medical, scientific and patient organization grants and charitable contributions made in the first quarter of this year, part of an ongoing drive th<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: May 2008 Update: Sprint Fidelis Lead Wire Failures Due To Design Flaw, Not Doctors]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_May_2008_Update_Sprint_Fidelis_Lead_Wire_Failures_Due_To_Design_Flaw_Not_Doctors/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_May_2008_Update_Sprint_Fidelis_Lead_Wire_Failures_Due_To_Design_Flaw_Not_Doctors/</comments>
<pubDate>Thu, 15 May 2008 03:04:41 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_May_2008_Update_Sprint_Fidelis_Lead_Wire_Failures_Due_To_Design_Flaw_Not_Doctors/</guid>
<description><![CDATA[As Dr. Robert Hauser said:  &quot;Just because a device is FDA-approved does not necessarily mean it is safe.&quot;<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Lapatinib (Tykerb/Tyverb) to be investigated in landmark early breast cancer trial]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Lapatinib_TykerbTyverb_to_be_investigated_in_landmark_early_breast_cancer_trial/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Lapatinib_TykerbTyverb_to_be_investigated_in_landmark_early_breast_cancer_trial/</comments>
<pubDate>Thu, 15 May 2008 03:04:30 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Lapatinib_TykerbTyverb_to_be_investigated_in_landmark_early_breast_cancer_trial/</guid>
<description><![CDATA[GlaxoSmithKline (GSK), in collaboration with the Breast International Group (BIG), a leading academic breast cancer research network, and one of its member groups, the Spanish Breast Cancer Cooperati<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Who's Who in the Biosimilar Space?]]></title>
<link>http://www.worldpharmanews.net/Blogs/Whos_Who_in_the_Biosimilar_Space-1/</link>
<comments>http://www.worldpharmanews.net/Blogs/Whos_Who_in_the_Biosimilar_Space-1/</comments>
<pubDate>Wed, 14 May 2008 00:43:52 CEST</pubDate>
<dc:creator>cliffmz</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Whos_Who_in_the_Biosimilar_Space-1/</guid>
<description><![CDATA[In 2004, the European Commission adopted a new directive that paved the way for legal approval of biosimilars in the European Union (EU). To date, five (5) biosimilars have garnered marketing approva<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Scientists solve mystery of why arsenic works in cancer drugs]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Scientists_solve_mystery_of_why_arsenic_works_in_cancer_drugs/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Scientists_solve_mystery_of_why_arsenic_works_in_cancer_drugs/</comments>
<pubDate>Wed, 14 May 2008 00:43:38 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Scientists_solve_mystery_of_why_arsenic_works_in_cancer_drugs/</guid>
<description><![CDATA[Since the 18th century, several arsenic compounds have been used as medicines, including arsenic trioxide (ATO) which is commonly prescribed in the treatment of certain types of cancer. Although they<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: May 2008 Congressional Hearing On Federal Preemption Of Drug And Medical Device Lawsuits]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_May_2008_Congressional_Hearing_On_Federal_Preemption_Of_Drug_And_Medical_Device_Lawsuits/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_May_2008_Congressional_Hearing_On_Federal_Preemption_Of_Drug_And_Medical_Device_Lawsuits/</comments>
<pubDate>Tue, 13 May 2008 00:50:19 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_May_2008_Congressional_Hearing_On_Federal_Preemption_Of_Drug_And_Medical_Device_Lawsuits/</guid>
<description><![CDATA[On May 14, 2008 a House of Representative's Committee will convene a hearing to explore the legal doctrine of federal preemption in the context of product liabilitliability lawsuits involving FDA-ap<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Scientific Misconduct Blog: LSD and the corruption of medicine (Part V):  The UK connection]]></title>
<link>http://www.worldpharmanews.net/Blogs/Scientific_Misconduct_Blog_LSD_and_the_corruption_of_medicine_Part_V__The_UK_connection/</link>
<comments>http://www.worldpharmanews.net/Blogs/Scientific_Misconduct_Blog_LSD_and_the_corruption_of_medicine_Part_V__The_UK_connection/</comments>
<pubDate>Tue, 13 May 2008 00:50:07 CEST</pubDate>
<dc:creator>SMB</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Scientific_Misconduct_Blog_LSD_and_the_corruption_of_medicine_Part_V__The_UK_connection/</guid>
<description><![CDATA[Last of a 5 part series<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: Recall Notice For Digitek Marketed Under Bertek Label Goes Back To March 2006]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Recall_Notice_For_Digitek_Marketed_Under_Bertek_Label_Goes_Back_To_March_2006/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Recall_Notice_For_Digitek_Marketed_Under_Bertek_Label_Goes_Back_To_March_2006/</comments>
<pubDate>Tue, 13 May 2008 00:49:29 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Recall_Notice_For_Digitek_Marketed_Under_Bertek_Label_Goes_Back_To_March_2006/</guid>
<description><![CDATA[North Carolina Board Of Pharmacy Has Posted A Copy Of The Bertek Digitek Drug Recall Notice On Its Web Site<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Boehringer Ingelheim announces commitment to progressing science with the Bouquet Studies]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Boehringer_Ingelheim_announces_commitment_to_progressing_science_with_the_Bouquet_Studies/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Boehringer_Ingelheim_announces_commitment_to_progressing_science_with_the_Bouquet_Studies/</comments>
<pubDate>Tue, 13 May 2008 00:49:19 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Boehringer_Ingelheim_announces_commitment_to_progressing_science_with_the_Bouquet_Studies/</guid>
<description><![CDATA[Data announced at the American College of Obstetricians and Gynaecologists (ACOG) annual clinical meeting suggest that up to one in ten women are suffering from a condition called hypoactive sexual d<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pharmalot  Who Is That Pharmalot Guy?]]></title>
<link>http://www.worldpharmanews.net/Blogs/Pharmalot_-_Who_Is_That_Pharmalot_Guy/</link>
<comments>http://www.worldpharmanews.net/Blogs/Pharmalot_-_Who_Is_That_Pharmalot_Guy/</comments>
<pubDate>Mon, 12 May 2008 11:52:43 CEST</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Pharmalot_-_Who_Is_That_Pharmalot_Guy/</guid>
<description><![CDATA[Although we slave all day and into the night over a warm laptop at the Pharmalot corporate headquarters, every so often we venture out to speak to this or that group about pharma matters or blogging.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Actemra inhibits joint damage and improves physical function of patients with Rheumatoid Arthritis]]></title>
<link>http://www.worldpharmanews.net/Product/Actemra_inhibits_joint_damage_and_improves_physical_function_of_patients_with_Rheumatoid_Arthritis/</link>
<comments>http://www.worldpharmanews.net/Product/Actemra_inhibits_joint_damage_and_improves_physical_function_of_patients_with_Rheumatoid_Arthritis/</comments>
<pubDate>Sun, 11 May 2008 15:36:26 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Actemra_inhibits_joint_damage_and_improves_physical_function_of_patients_with_Rheumatoid_Arthritis/</guid>
<description><![CDATA[Roche announced that Actemra (tocilizumab) can significantly inhibit structura[1] damage to joints in patients with rheumatoid arthritis (RA), a critical measure of effectiveness of an RA treatment. <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pharmalot  FDA Scraps Helsinki Rule On Human Subjects]]></title>
<link>http://www.worldpharmanews.net/Blogs/Pharmalot_-_FDA_Scraps_Helsinki_Rule_On_Human_Subjects/</link>
<comments>http://www.worldpharmanews.net/Blogs/Pharmalot_-_FDA_Scraps_Helsinki_Rule_On_Human_Subjects/</comments>
<pubDate>Sun, 11 May 2008 15:36:15 CEST</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Pharmalot_-_FDA_Scraps_Helsinki_Rule_On_Human_Subjects/</guid>
<description><![CDATA[Drugmakers will soon be able to use data from foreign clinical trials in new drug applications even if trials only compare new products to placebos instead of best available treatments. The change de<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[International study to evaluate efficacy and safety in treating a leading cause of blindness]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/International_study_to_evaluate_efficacy_and_safety_in_treating_a_leading_cause_of_blindness/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/International_study_to_evaluate_efficacy_and_safety_in_treating_a_leading_cause_of_blindness/</comments>
<pubDate>Sat, 10 May 2008 00:09:00 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/International_study_to_evaluate_efficacy_and_safety_in_treating_a_leading_cause_of_blindness/</guid>
<description><![CDATA[Bayer HealthCare AG and development partner Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: Ortho Evra Recall Requested By Public Citizen Due To Blood Clot Risks]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Ortho_Evra_Recall_Requested_By_Public_Citizen_Due_To_Blood_Clot_Risks/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Ortho_Evra_Recall_Requested_By_Public_Citizen_Due_To_Blood_Clot_Risks/</comments>
<pubDate>Fri, 09 May 2008 00:31:21 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Ortho_Evra_Recall_Requested_By_Public_Citizen_Due_To_Blood_Clot_Risks/</guid>
<description><![CDATA[<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Highlight Potential of Novel Oral Compound for Gaucher Disease]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Highlight_Potential_of_Novel_Oral_Compound_for_Gaucher_Disease/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Highlight_Potential_of_Novel_Oral_Compound_for_Gaucher_Disease/</comments>
<pubDate>Fri, 09 May 2008 00:31:11 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Highlight_Potential_of_Novel_Oral_Compound_for_Gaucher_Disease/</guid>
<description><![CDATA[Genzyme Corp. (NASDAQ: GENZ) reported today that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compo<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Jacob Fleming's 4th Annual Enhancing Clinical Trial Processes]]></title>
<link>http://www.worldpharmanews.net/Conferences_Events/Jacob_Flemings_4th_Annual_Enhancing_Clinical_Trial_Processes/</link>
<comments>http://www.worldpharmanews.net/Conferences_Events/Jacob_Flemings_4th_Annual_Enhancing_Clinical_Trial_Processes/</comments>
<pubDate>Fri, 09 May 2008 00:30:59 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Conferences &amp; Events</category>
<guid>http://www.worldpharmanews.net/Conferences_Events/Jacob_Flemings_4th_Annual_Enhancing_Clinical_Trial_Processes/</guid>
<description><![CDATA[14th-15th May, 2008, AmsterdamJacob Fleming's 4th Annual Enhancing Clinical Trial Processes conference will provide the answers to your questions. Industry experts will present real life case stud<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Innovative Medicines Initiative to give boost to Europe's pharmaceutical industry]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Innovative_Medicines_Initiative_to_give_boost_to_Europes_pharmaceutical_industry/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Innovative_Medicines_Initiative_to_give_boost_to_Europes_pharmaceutical_industry/</comments>
<pubDate>Thu, 08 May 2008 00:04:53 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Innovative_Medicines_Initiative_to_give_boost_to_Europes_pharmaceutical_industry/</guid>
<description><![CDATA[With the launch of its first call for proposals, the Innovative Medicines Initiative (IMI) got underway on 30 April. Joining forces, the European Commission and the European Federation of Pharmaceuti<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bayer Schering Pharma to market new low-dose oral contraceptive YAZ in Europe]]></title>
<link>http://www.worldpharmanews.net/Product/Bayer_Schering_Pharma_to_market_new_low-dose_oral_contraceptive_YAZ%AE_in_Europe/</link>
<comments>http://www.worldpharmanews.net/Product/Bayer_Schering_Pharma_to_market_new_low-dose_oral_contraceptive_YAZ%AE_in_Europe/</comments>
<pubDate>Thu, 08 May 2008 00:04:40 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Bayer_Schering_Pharma_to_market_new_low-dose_oral_contraceptive_YAZ%AE_in_Europe/</guid>
<description><![CDATA[Bayer Schering Pharma's new low-dose oral contraceptive YAZ® has been approved in the EU. YAZ® will be the first oral contraceptive on the European market containing the unique progestin drospirenon<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: Extent Of Digitek Recall Remains A Mystery Ten Days Later; Patients Are Left In The Dark]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Extent_Of_Digitek_Recall_Remains_A_Mystery_Ten_Days_Later_Patients_Are_Left_In_The_Dark/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Extent_Of_Digitek_Recall_Remains_A_Mystery_Ten_Days_Later_Patients_Are_Left_In_The_Dark/</comments>
<pubDate>Wed, 07 May 2008 00:09:47 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Extent_Of_Digitek_Recall_Remains_A_Mystery_Ten_Days_Later_Patients_Are_Left_In_The_Dark/</guid>
<description><![CDATA[Heart Medication Sold By Mylan Was Made In Actavis Plant That Received FDA Letter About Manufacturing Problems Over A Year Ago<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[European Commission grants full approval of HIV protease inhibitor, tipranavir (Aptivus)]]></title>
<link>http://www.worldpharmanews.net/Product/European_Commission_grants_full_approval_of_HIV_protease_inhibitor_tipranavir_Aptivus%AE/</link>
<comments>http://www.worldpharmanews.net/Product/European_Commission_grants_full_approval_of_HIV_protease_inhibitor_tipranavir_Aptivus%AE/</comments>
<pubDate>Wed, 07 May 2008 00:09:37 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/European_Commission_grants_full_approval_of_HIV_protease_inhibitor_tipranavir_Aptivus%AE/</guid>
<description><![CDATA[Boehringer Ingelheim announced that the European Commission has given the full marketing authorisation to its HIV protease inhibitor (PI), Aptivus® (tipranavir). The Commission has fully approved Apt<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novo Nordisk researchers nominated for Europe's top innovation prize]]></title>
<link>http://www.worldpharmanews.net/Corporate/Novo_Nordisk_researchers_nominated_for_Europes_top_innovation_prize/</link>
<comments>http://www.worldpharmanews.net/Corporate/Novo_Nordisk_researchers_nominated_for_Europes_top_innovation_prize/</comments>
<pubDate>Tue, 06 May 2008 00:10:08 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/Novo_Nordisk_researchers_nominated_for_Europes_top_innovation_prize/</guid>
<description><![CDATA[A team of researchers from Novo Nordisk is nominated for Europe's top innovation prize, Inventor of the Year 2008 Award, that will be presented at a ceremony in Ljubljana, Slovenia, on 6 May by the <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[GlaxoSmithKline commences tender offer to acquire Sirtris Pharmaceuticals]]></title>
<link>http://www.worldpharmanews.net/Financial/GlaxoSmithKline_commences_tender_offer_to_acquire_Sirtris_Pharmaceuticals/</link>
<comments>http://www.worldpharmanews.net/Financial/GlaxoSmithKline_commences_tender_offer_to_acquire_Sirtris_Pharmaceuticals/</comments>
<pubDate>Tue, 06 May 2008 00:09:56 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/GlaxoSmithKline_commences_tender_offer_to_acquire_Sirtris_Pharmaceuticals/</guid>
<description><![CDATA[GlaxoSmithKline plc (GSK) announced that Fountain Acquisition Corporation, a wholly-owned subsidiary of GSK, is commencing a cash tender offer to purchase all outstanding shares of common stock of Si<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[LSD and the corruption of medicine (Part I):  Invention and the beginnings of MK-ULTRA]]></title>
<link>http://www.worldpharmanews.net/Blogs/LSD_and_the_corruption_of_medicine_Part_I__Invention_and_the_beginnings_of_MK-ULTRA/</link>
<comments>http://www.worldpharmanews.net/Blogs/LSD_and_the_corruption_of_medicine_Part_I__Invention_and_the_beginnings_of_MK-ULTRA/</comments>
<pubDate>Mon, 05 May 2008 00:04:44 CEST</pubDate>
<dc:creator>SMB</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/LSD_and_the_corruption_of_medicine_Part_I__Invention_and_the_beginnings_of_MK-ULTRA/</guid>
<description><![CDATA[On the death of the inventor of LSD<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: FDA Says It Doesn't Know How Long Defective Digitek / Digoxin Pills Were Sold]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_FDA_Says_It_Doesnt_Know_How_Long_Defective_Digitek__Digoxin_Pills_Were_Sold/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_FDA_Says_It_Doesnt_Know_How_Long_Defective_Digitek__Digoxin_Pills_Were_Sold/</comments>
<pubDate>Mon, 05 May 2008 00:04:34 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_FDA_Says_It_Doesnt_Know_How_Long_Defective_Digitek__Digoxin_Pills_Were_Sold/</guid>
<description><![CDATA[The facts surrounding the late April 2008 recall of Digitek (digoxin) pills that may have twice the active ingredient is becoming less clear as we learn more in the days following the FDA recall.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Big Pharma and Biotech Assail US Patent Laws :]]></title>
<link>http://www.worldpharmanews.net/Corporate/Big_Pharma_and_Biotech_Assail_US_Patent_Laws_/</link>
<comments>http://www.worldpharmanews.net/Corporate/Big_Pharma_and_Biotech_Assail_US_Patent_Laws_/</comments>
<pubDate>Sun, 04 May 2008 21:09:40 CEST</pubDate>
<dc:creator>cliffmz</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/Big_Pharma_and_Biotech_Assail_US_Patent_Laws_/</guid>
<description><![CDATA[Brand name pharmaceutical and biotechnology companies have been quietly spending millions to lobby Congress for changes in US patent law. Specifically, these companies want to overhaul the intellectu<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[A New Age is Dawning: FDA to Go On a Hiring Spree!]]></title>
<link>http://www.worldpharmanews.net/Blogs/A_New_Age_is_Dawning_FDA_to_Go_On_a_Hiring_Spree/</link>
<comments>http://www.worldpharmanews.net/Blogs/A_New_Age_is_Dawning_FDA_to_Go_On_a_Hiring_Spree/</comments>
<pubDate>Sun, 04 May 2008 21:09:07 CEST</pubDate>
<dc:creator>cliffmz</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/A_New_Age_is_Dawning_FDA_to_Go_On_a_Hiring_Spree/</guid>
<description><![CDATA[The Food and Drug Administration (FDA) announced today that it wants to hire 1,300 biologists, chemists, medical officers and others over the next several months. The agency currently employs more th<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Abbott, Takeda Conclude TAP Joint Venture]]></title>
<link>http://www.worldpharmanews.net/Corporate/Abbott_Takeda_Conclude_TAP_Joint_Venture/</link>
<comments>http://www.worldpharmanews.net/Corporate/Abbott_Takeda_Conclude_TAP_Joint_Venture/</comments>
<pubDate>Sun, 04 May 2008 21:08:55 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/Abbott_Takeda_Conclude_TAP_Joint_Venture/</guid>
<description><![CDATA[Abbott and Takeda Pharmaceutical Company Limited have concluded their TAP Pharmaceutical Products Inc. (TAP) joint venture. The closing of the agreement to evenly divide the value of the more than 30<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Lundbeck expands geographical rights for Circadin]]></title>
<link>http://www.worldpharmanews.net/Product/Lundbeck_expands_geographical_rights_for_Circadin%AE/</link>
<comments>http://www.worldpharmanews.net/Product/Lundbeck_expands_geographical_rights_for_Circadin%AE/</comments>
<pubDate>Fri, 02 May 2008 00:06:16 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Lundbeck_expands_geographical_rights_for_Circadin%AE/</guid>
<description><![CDATA[H. Lundbeck A/S and Neurim Pharmaceuticals Ltd. announced that Lundbeck has obtained expanded exclusive rights to commercialize Circadin® in Asia, Latin America and other major markets such as Austra<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Esperion Therapeutics Completes $22.75 M Series A Financing]]></title>
<link>http://www.worldpharmanews.net/Financial/Esperion_Therapeutics_Completes_22-75_M_Series_A_Financing/</link>
<comments>http://www.worldpharmanews.net/Financial/Esperion_Therapeutics_Completes_22-75_M_Series_A_Financing/</comments>
<pubDate>Fri, 02 May 2008 00:06:06 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Esperion_Therapeutics_Completes_22-75_M_Series_A_Financing/</guid>
<description><![CDATA[Esperion Therapeutics, Inc. a biopharmaceutical company formed to focus on the discovery and development of compounds to treat cardiovascular and metabolic disease, today announced that it has been l<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: Digitek Digoxin Recall: Tablets May Be Double The Normal Dose]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Digitek_Digoxin_Recall_Tablets_May_Be_Double_The_Normal_Dose/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Digitek_Digoxin_Recall_Tablets_May_Be_Double_The_Normal_Dose/</comments>
<pubDate>Thu, 01 May 2008 00:09:02 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Digitek_Digoxin_Recall_Tablets_May_Be_Double_The_Normal_Dose/</guid>
<description><![CDATA[In an April 28, 2008 MedWatch Safety Alert about Digitek (digoxin tablets), the FDA informed doctors and patients that this prescription medication is the subject of a nationwide Class I recall.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca Submits sNDA for SYMBICORT for COPD Treatment]]></title>
<link>http://www.worldpharmanews.net/Product/AstraZeneca_Submits_sNDA_for_SYMBICORT%AE_for_COPD_Treatment/</link>
<comments>http://www.worldpharmanews.net/Product/AstraZeneca_Submits_sNDA_for_SYMBICORT%AE_for_COPD_Treatment/</comments>
<pubDate>Thu, 01 May 2008 00:08:52 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/AstraZeneca_Submits_sNDA_for_SYMBICORT%AE_for_COPD_Treatment/</guid>
<description><![CDATA[AstraZeneca today announced submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) to seek approval of a new indication for SYMBICORT® (budesonide/formo<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Survey Takes Pulse of eHealth in Europe and Prescribes Wider ICT use Among Doctors]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Survey_Takes_Pulse_of_eHealth_in_Europe_and_Prescribes_Wider_ICT_use_Among_Doctors/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Survey_Takes_Pulse_of_eHealth_in_Europe_and_Prescribes_Wider_ICT_use_Among_Doctors/</comments>
<pubDate>Thu, 01 May 2008 00:08:42 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Survey_Takes_Pulse_of_eHealth_in_Europe_and_Prescribes_Wider_ICT_use_Among_Doctors/</guid>
<description><![CDATA[The European Commission published a pan-European survey on electronic services in healthcare (eHealth) that shows 87% of European doctors (General Practitioners) use a computer, 48% with a broadband <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novo Nordisk will donate a licence to its small molecule compound library]]></title>
<link>http://www.worldpharmanews.net/Corporate/Novo_Nordisk_will_donate_a_licence_to_its_small_molecule_compound_library/</link>
<comments>http://www.worldpharmanews.net/Corporate/Novo_Nordisk_will_donate_a_licence_to_its_small_molecule_compound_library/</comments>
<pubDate>Wed, 30 Apr 2008 00:03:58 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/Novo_Nordisk_will_donate_a_licence_to_its_small_molecule_compound_library/</guid>
<description><![CDATA[Novo Nordisk will donate a licence to its small molecule compound library to the National Center for Drug Screening (NCDS) affiliated to Shanghai Institute of Materia Medica, Chinese Academy of Scien<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pharmalot  Has Vytorin Created New FDA Approval Hurdles?]]></title>
<link>http://www.worldpharmanews.net/Blogs/Pharmalot_-_Has_Vytorin_Created_New_FDA_Approval_Hurdles/</link>
<comments>http://www.worldpharmanews.net/Blogs/Pharmalot_-_Has_Vytorin_Created_New_FDA_Approval_Hurdles/</comments>
<pubDate>Wed, 30 Apr 2008 00:03:45 CEST</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Pharmalot_-_Has_Vytorin_Created_New_FDA_Approval_Hurdles/</guid>
<description><![CDATA[Given the concerns over how widely marketed Vytorin and Zetia were over the past few years, the FDA response to Genzyme and Isis raises an interesting thought - whether the agency is no longer willin<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: FDA's 2007 Report On Outstanding Post-approval Studies: No Progress Made By Big Pharma]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_FDAs_2007_Report_On_Outstanding_Post-approval_Studies_No_Progress_Made_By_Big_Pharma/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_FDAs_2007_Report_On_Outstanding_Post-approval_Studies_No_Progress_Made_By_Big_Pharma/</comments>
<pubDate>Tue, 29 Apr 2008 00:12:15 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_FDAs_2007_Report_On_Outstanding_Post-approval_Studies_No_Progress_Made_By_Big_Pharma/</guid>
<description><![CDATA[Each year the FDA issues a so-called &quot;report card&quot; on how the pharmaceutical companies are doing as regards post-approval studies for their products that have been approved for sale in the U.S.<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Follicular lymphoma: EU approval for Zevalin as First-Line Consolidation Treatment]]></title>
<link>http://www.worldpharmanews.net/Product/Follicular_lymphoma_EU_approval_for_Zevalin%AE_as_First-Line_Consolidation_Treatment/</link>
<comments>http://www.worldpharmanews.net/Product/Follicular_lymphoma_EU_approval_for_Zevalin%AE_as_First-Line_Consolidation_Treatment/</comments>
<pubDate>Tue, 29 Apr 2008 00:12:04 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Follicular_lymphoma_EU_approval_for_Zevalin%AE_as_First-Line_Consolidation_Treatment/</guid>
<description><![CDATA[The European Commission has extended the marketing authorization for Zevalin® ([90Y]-ibritumomab tiuxetan) in Europe. Zevalin can now be used in the course of a first-line therapy after remission ind<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Amgen's First Quarter 2008 Adjusted Earnings Per Share Increased 4 percent to $1.12]]></title>
<link>http://www.worldpharmanews.net/Financial/Amgens_First_Quarter_2008_Adjusted_Earnings_Per_Share_Increased_4_percent_to_1-12/</link>
<comments>http://www.worldpharmanews.net/Financial/Amgens_First_Quarter_2008_Adjusted_Earnings_Per_Share_Increased_4_percent_to_1-12/</comments>
<pubDate>Mon, 28 Apr 2008 12:30:33 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Amgens_First_Quarter_2008_Adjusted_Earnings_Per_Share_Increased_4_percent_to_1-12/</guid>
<description><![CDATA[Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.12 for the first quarter of 2008, an increase of 4 percent compared to<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pharmalot  FDA's Off-Label Guidance: Fantasy Or Framework?]]></title>
<link>http://www.worldpharmanews.net/Blogs/Pharmalot_-_FDAs_Off-Label_Guidance_Fantasy_Or_Framework/</link>
<comments>http://www.worldpharmanews.net/Blogs/Pharmalot_-_FDAs_Off-Label_Guidance_Fantasy_Or_Framework/</comments>
<pubDate>Mon, 28 Apr 2008 00:06:22 CEST</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Pharmalot_-_FDAs_Off-Label_Guidance_Fantasy_Or_Framework/</guid>
<description><![CDATA[Should drug and device makers be allowed to provide docs with medical and scientific journal articles concerning uses of their products that have not been approved by the FDA? That's the question as<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer Enters into Research Consortium to Expand Understanding of Diabetes and Obesity Pathobiology]]></title>
<link>http://www.worldpharmanews.net/Corporate/Pfizer_Enters_into_Research_Consortium_to_Expand_Understanding_of_Diabetes_and_Obesity_Pathobiology/</link>
<comments>http://www.worldpharmanews.net/Corporate/Pfizer_Enters_into_Research_Consortium_to_Expand_Understanding_of_Diabetes_and_Obesity_Pathobiology/</comments>
<pubDate>Sun, 27 Apr 2008 00:23:05 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/Pfizer_Enters_into_Research_Consortium_to_Expand_Understanding_of_Diabetes_and_Obesity_Pathobiology/</guid>
<description><![CDATA[Pfizer has entered into a collaboration agreement with four major research universities - University of California, Santa Barbara (UCSB); Caltech; the Massachusetts Institute of Technology; and Unive<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Two Merck Medicines Recommended for Approval in the European Union]]></title>
<link>http://www.worldpharmanews.net/Product/Two_Merck_Medicines_Recommended_for_Approval_in_the_European_Union/</link>
<comments>http://www.worldpharmanews.net/Product/Two_Merck_Medicines_Recommended_for_Approval_in_the_European_Union/</comments>
<pubDate>Sat, 26 Apr 2008 00:02:01 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Two_Merck_Medicines_Recommended_for_Approval_in_the_European_Union/</guid>
<description><![CDATA[Merck &amp; Co., Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended two medicines for marketing approval in the European Union <br/><br/>1 Vote(s) ]]></description>
</item>

</channel>
</rss>
